The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Aptevo Therapeutics Inc shares valued at $20,134 were purchased by Grant Grady III on Nov 10 ’25. At $1.49 per share, Grant Grady III acquired 13,513 shares. The insider’s holdings grew to 13,514 shares worth approximately $16487.079999999998 following the completion of this transaction.
As published in their initiating research note from Ladenburg Thalmann on November 05, 2018, Aptevo Therapeutics Inc [APVO] has been a Buy.
Analyzing APVO Stock Performance
On last trading session, Aptevo Therapeutics Inc [NASDAQ: APVO] plunged -7.58% to $1.22. The stock’s lowest price that day was $1.21, but it reached a high of $1.31 in the same session. During the last five days, there has been a drop of approximately -17.57%. Over the course of the year, Aptevo Therapeutics Inc shares have dropped approximately -99.22%. Shares of the company reached a 52-week high of $109.8000 on 01/07/25 and a 52-week low of $1.2100 on 11/19/25.
Support And Resistance Levels for Aptevo Therapeutics Inc (APVO)
According to the 24-hour chart, there is a support level at 1.1833, which, if violated, would cause prices to drop to 1.1467. In the upper region, resistance lies at 1.2833. The next price resistance is at 1.3467. RSI (Relative Strength Index) is 33.06 on the 14-day chart, showing neutral technical sentiment.
Is Aptevo Therapeutics Inc subject to short interest?
Stocks of Aptevo Therapeutics Inc saw a sharp steep in short interest on 2025-10-31 dropping by -0.89 million shares to 0.5 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 1.39 million shares. A decline of -177.86% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.13 of the overall float, the days-to-cover ratio (short ratio) decline to 0.13.
